ZEVTERA
LOE Approachingceftobiprole medocaril sodium
NDAINTRAVENOUSPOWDERPriority Review
Approved
Apr 2024
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEVTERA (ceftobiprole medocaril sodium) is a fifth-generation cephalosporin administered intravenously as a powder formulation. It is indicated for bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-positive pathogens. The drug works by inhibiting bacterial cell wall synthesis, providing broad-spectrum coverage in hospital and acute care settings.
LOE Approaching2.4 years to LOE
Recent approval in 2024 with limited commercial data; small linked job count (0) suggests early-stage team building or integration into existing antibiotic portfolios.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.